All News

Despite awareness that many cancer survivors suffer from treatment-related sexual dysfunction, sexual aids and resources are not readily available to them — even at leading cancer centers throughout the United States.

Eighty-nine percent of caregivers of young adult colorectal cancer survivors are depressed because they can’t take the pain away, according to findings from the Raymond Foundation, an advocacy organization that aims to eradicate colon cancer.

A guy with breast cancer reveals a secret that can save your life.

A look back on that time more than 200 men grabbed their balls in public.

The Food and Drug Administration (FDA) approved the two-drug combination Tafinlar (dabrafenib) and Mekinist (trametinib) to treat patients with metastatic or unresectable anaplastic thyroid cancer (ATC), whose tumors harbor the BRAF V600E mutation.

I think being an athlete is what saved my life.

Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.

How a clown named Miss Sydney helped so many kids battling cancer.

Saying goodbye to your old normal is necessary when you're faced with cancer. The new normal is a vitally important part of a cancer survivor's post diagnosis timeline.

Girls Gone Rx sponsors all-female fitness competitions to raise money for Bright Pink, a nonprofit that focuses on prevention and early detection of breast and ovarian cancer.

Palliative care can be used at all cancer stages, and can drastically improve patients' quality of life.

I've been a survivor for over a year, but I always say, "I am surviving." Why?

As suspected, the average early mortality rate improved overall during the study period. But while evaluating the data, researchers noticed something interesting about the difference in early mortality at the NCI-designated cancer centers compared to non-NCI-designated cancer centers.

A musician with breast cancer reflects on the power of music in our health and healing.

It may take some time, but finding the right oncologist can be like striking gold.

After radiation, as the skin heals, a compassionate dermatologist can help us to monitor any lingering side-effects.

Survivorship care plans lag more than a decade after launch.

Alternative cancer treatment takes a moderate amount of effort, but this survivor thinks it's worth it.

One expert discusses current standard-of-care regimens as well as new combinations on the horizon for patients with myeloma who are not eligible to receive a stem cell transplant.

With the number of treatment options consistently increasing, tumor testing is growing more important to personalize care for women with ovarian cancer.

The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) – a CAR-T cell therapy – for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).

Admission is by invitation only and the dues are high. Once we're in, we're members for life.

Breast cancer survivor tries to decide if she is spoiled and ungrateful or, if like many cancer survivors, she just needs a little safety valve to blow off steam.

An evening of storytelling among women afflicted by ovarian cancer – whether it be their own diagnosis or a loved one’s – helped to empower individuals to find their voice.

Perspective is important with cancer and remission.

Don't be scared to write "legacy letters." Here's advice on getting started and why it matters from a woman with metastatic breast cancer

The combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted Food and Drug Administration (FDA) approval for the treatment of patients with BRAF V600E– or V600K–positive stage 3 melanoma following complete resection.

The Food and Drug Administration (FDA) granted a priority review to a biologics license application (BLA) for an immunotherapy agent – cemiplimab – to be used to treat metastatic cutaneous squamous cell carcinoma (a type of skin cancer; CSCC) or patients with locally advanced CSCC who are not eligible for surgery.

When I contemplate this latest benchmark in my life, my 15th year surviving stage 3b breast cancer, I confess there are times when I feel like it was just yesterday the Trickster Coyote – the Native American mythical creature of evil and bad omen – blindsided me, bent on taking me down in the one sacred place I felt I could take refuge from the world: my home.

The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), according to Merck (MSD), the manufacturer of the PD-1 inhibitor.